Free Trial

Cytokinetics (CYTK) News Today

→ How Biden has already won 2024 (From Porter & Company) (Ad)
Free CYTK Stock Alerts
$52.79
+0.51 (+0.98%)
(As of 06/7/2024 08:51 PM ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends
June 9 at 10:53 AM | marketbeat.com
62,229 Shares in Cytokinetics, Incorporated (NASDAQ:CYTK) Purchased by Seven Eight Capital LP
Seven Eight Capital LP bought a new position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 62,229 shares of the biopharmaceutical company's sto
June 9 at 4:50 AM | americanbankingnews.com
Cytokinetics, Incorporated (NASDAQ:CYTK) CEO Sells $1,099,125.00 in Stock
June 8 at 8:13 PM | marketbeat.com
Platinum Investment Management Ltd. Buys Shares of 19,138 Cytokinetics, Incorporated (NASDAQ:CYTK)
Platinum Investment Management Ltd. bought a new stake in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 19,138 shares of
June 8 at 8:30 AM | insidertrades.com
Cytokinetics, Incorporated (NASDAQ:CYTK) CEO Robert I. Blum Sells 22,500 Shares
June 8 at 1:36 AM | americanbankingnews.com
B. Riley Weighs in on Cytokinetics, Incorporated's Q2 2024 Earnings (NASDAQ:CYTK)
June 7 at 11:15 PM | marketbeat.com
Cytokinetics, Incorporated (NASDAQ:CYTK) is RTW Investments LP's 10th Largest Position
RTW Investments LP reduced its stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 1.9% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,525,080 shares of the biopharmaceutical company's stock after selling 49
June 7 at 4:34 PM | marketbeat.com
Robert I. Blum Sells 22,500 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) Stock
Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) CEO Robert I. Blum sold 22,500 shares of the business's stock in a transaction that occurred on Tuesday, June 4th. The stock was sold at an average price of $48.85, for a total value of $1,099,125.00. Following the transaction, the chief executive officer now owns 439,145 shares in the company, valued at $21,452,233.25. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.
June 7 at 7:58 AM | americanbankingnews.com
Cytokinetics (NASDAQ:CYTK) Trading 6.9% Higher
June 7 at 6:23 AM | marketbeat.com
Q2 2024 EPS Estimates for Cytokinetics, Incorporated Boosted by Analyst (NASDAQ:CYTK)
Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) - B. Riley boosted their Q2 2024 earnings per share (EPS) estimates for Cytokinetics in a research report issued to clients and investors on Tuesday, June 4th. B. Riley analyst M. Mamtani now expects that the biopharmaceutical company will po
June 7 at 6:14 AM | americanbankingnews.com
Robert Arthur Harrington Sells 1,580 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) Stock
June 6, 2024 | insidertrades.com
Insider Selling: Cytokinetics, Incorporated (NASDAQ:CYTK) Director Sells 1,580 Shares of Stock
June 6, 2024 | americanbankingnews.com
B. Riley Lowers Cytokinetics (NASDAQ:CYTK) Price Target to $92.00
June 5, 2024 | marketbeat.com
Cytokinetics, Incorporated (NASDAQ:CYTK) Director Sells $76,851.20 in Stock
Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) Director Robert Arthur Harrington sold 1,580 shares of the business's stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $48.64, for a total value of $76,851.20. Following the sale, the director now owns 15,541 shares of the company's stock, valued at approximately $755,914.24. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
June 5, 2024 | marketbeat.com
Cytokinetics (NASDAQ:CYTK) Stock Price Up 6.9%
Cytokinetics (NASDAQ:CYTK) Stock Price Up 6.9%
June 5, 2024 | marketbeat.com
Affinity Asset Advisors LLC Has $13.36 Million Stock Holdings in Cytokinetics, Incorporated (NASDAQ:CYTK)
Affinity Asset Advisors LLC lessened its stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 30.5% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 160,000 shares of the biopharmaceutical company's stock after selling 70
June 5, 2024 | americanbankingnews.com
Cytokinetics, Incorporated (NASDAQ:CYTK) CAO Robert Wong Sells 13,011 Shares
June 4, 2024 | marketbeat.com
Rhenman & Partners Asset Management AB Has $12.52 Million Stock Position in Cytokinetics, Incorporated (NASDAQ:CYTK)
Rhenman & Partners Asset Management AB lowered its holdings in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 25.0% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 149,912 shares of the biopharmaceutical company
June 4, 2024 | globenewswire.com
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 4, 2024 | insidertrades.com
Robert Wong Sells 13,011 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) Stock
June 3, 2024 | marketbeat.com
Rafferty Asset Management LLC Purchases 16,353 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)
Rafferty Asset Management LLC raised its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 6.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 263,275 shares of the biophar
June 2, 2024 | marketbeat.com
Eagle Asset Management Inc. Has $16.99 Million Stock Position in Cytokinetics, Incorporated (NASDAQ:CYTK)
Eagle Asset Management Inc. lessened its holdings in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 48.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 203,547 shares of the biopharmaceutical company's
May 31, 2024 | americanbankingnews.com
Truist Financial Lowers Cytokinetics (NASDAQ:CYTK) Price Target to $70.00
May 31, 2024 | americanbankingnews.com
Cytokinetics (NASDAQ:CYTK) PT Lowered to $78.00 at JMP Securities
May 29, 2024 | globenewswire.com
Cytokinetics to Participate in June Investor Conferences
May 29, 2024 | marketbeat.com
Cytokinetics (NASDAQ:CYTK) Shares Up 2%
Cytokinetics (NASDAQ:CYTK) Stock Price Up 2%
May 28, 2024 | globenewswire.com
Cytokinetics Announces Closing of Public Offering of Common Stock
May 28, 2024 | marketbeat.com
JMP Securities Lowers Cytokinetics (NASDAQ:CYTK) Price Target to $78.00
JMP Securities cut their price objective on shares of Cytokinetics from $106.00 to $78.00 and set a "market outperform" rating on the stock in a research report on Tuesday.
May 28, 2024 | markets.businessinsider.com
Buy Rating Justified for Cytokinetics Amid Strong Capital Position and Promising Drug Pipeline
May 28, 2024 | marketbeat.com
Norges Bank Acquires Shares of 722,229 Cytokinetics, Incorporated (NASDAQ:CYTK)
Norges Bank acquired a new stake in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 722,229 shares of the biopharmaceutical company's stock, valued
May 27, 2024 | finance.yahoo.com
Is Cytokinetics, Incorporated (NASDAQ:CYTK) the Best Mid-Cap Healthcare Stock To Buy Now?
May 27, 2024 | marketbeat.com
HC Wainwright Weighs in on Cytokinetics, Incorporated's Q2 2024 Earnings (NASDAQ:CYTK)
Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) - Equities researchers at HC Wainwright lifted their Q2 2024 earnings per share estimates for shares of Cytokinetics in a research report issued on Thursday, May 23rd. HC Wainwright analyst J. Pantginis now expects that the biopharmaceutical
May 26, 2024 | uk.investing.com
Cytokinetics shares target cut, cites key financial transactions
May 25, 2024 | marketbeat.com
Franklin Resources Inc. Reduces Holdings in Cytokinetics, Incorporated (NASDAQ:CYTK)
Franklin Resources Inc. lowered its stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 41.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 660,682 shares of the biopharmace
May 24, 2024 | seekingalpha.com
Cytokinetics Decides To Go It Alone
May 24, 2024 | marketbeat.com
Leerink Partnrs Comments on Cytokinetics, Incorporated's FY2027 Earnings (NASDAQ:CYTK)
Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) - Analysts at Leerink Partnrs cut their FY2027 earnings per share (EPS) estimates for Cytokinetics in a research note issued on Wednesday, May 22nd. Leerink Partnrs analyst R. Ruiz now forecasts that the biopharmaceutical company will earn $3
May 23, 2024 | markets.businessinsider.com
Cytokinetics: Strong Buy Rating Backed by Significant Financial Support and Promising Pipeline
May 23, 2024 | msn.com
Why Cytokinetics (CYTK) Shares Are Falling
May 23, 2024 | marketbeat.com
Cytokinetics (NASDAQ:CYTK) Price Target Lowered to $60.00 at Bank of America
Bank of America cut their target price on shares of Cytokinetics from $70.00 to $60.00 and set a "neutral" rating for the company in a research report on Thursday.
May 23, 2024 | marketwatch.com
Cytokinetics Shares Drop 17% After Public Offering Prices
May 23, 2024 | markets.businessinsider.com
Analysts Are Bullish on These Healthcare Stocks: Cytokinetics (CYTK), Soleno Therapeutics (SLNO)
May 23, 2024 | marketbeat.com
Cytokinetics (NASDAQ:CYTK) Shares Gap Down After Analyst Downgrade
Cytokinetics (NASDAQ:CYTK) Shares Gap Down Following Analyst Downgrade
May 22, 2024 | globenewswire.com
Cytokinetics Announces Pricing of Public Offering of Common Stock
May 22, 2024 | globenewswire.com
Cytokinetics Announces Proposed Public Offering of Common Stock
May 22, 2024 | globenewswire.com
Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
May 22, 2024 | marketbeat.com
Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the fifteen analysts that are currently covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold rating and thirteen have given a buy rating to the com
May 21, 2024 | marketbeat.com
Trexquant Investment LP Increases Stock Holdings in Cytokinetics, Incorporated (NASDAQ:CYTK)
Trexquant Investment LP grew its stake in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 411.5% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 109,810 shares of the biopharmaceutical company's stock after buying an additional 88,342 shares during the
May 20, 2024 | marketbeat.com
Bridger Management LLC Makes New $1.88 Million Investment in Cytokinetics, Incorporated (NASDAQ:CYTK)
Bridger Management LLC bought a new stake in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 22,510 shares of the biopharmaceutical company's stock, valued at ap
May 17, 2024 | msn.com
Cytokinetics to Host Muscle Seminar
May 17, 2024 | globenewswire.com
Cytokinetics Hosts Muscle Biology-Focused Research Symposium: Contemporary Landscapes in Muscle Biology
May 16, 2024 | markets.businessinsider.com
Buy Rating Justified by Cytokinetics’ Aficamten Favorable Trial Data and Safety Profile
Get Cytokinetics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter.

Top 5 Tech Stocks to Buy for 2024 (Ad)

The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world's most powerful tech companies (including Microsoft, Intel, and Google) investing billions. And one tiny company will be the driving force behind this new tech revolution…

Click below for your free report "Top 5 Tech Stocks to Buy in 2024",

CYTK Media Mentions By Week

CYTK Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CYTK
News Sentiment
▼
0.75

0.76
▲
Average
Medical
News Sentiment

CYTK News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CYTK Articles
This Week
▼
27

8
▲
CYTK Articles
Average Week

Get Cytokinetics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

Related Companies:
Headlines Tools:
This page (NASDAQ:CYTK) was last updated on 6/10/2024 by MarketBeat.com Staff

From Our Partners
It's time to ween off Chinese lithium!
As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...
Smallcaps Daily | Sponsored
Top 5 Tech Stocks to Buy for 2024
The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...
Daily Market Alerts | Sponsored
Top 5 AI Stocks to Buy for 2024
The electric vehicle boom is accelerating – and fast.
Market Moving Trends | Sponsored
No Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for Free
Optimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...
Hedgeye | Sponsored
The Only Energy Play You Should Be Looking At
Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...
Wealthpin Pro | Sponsored
Write this ticker symbol down…
A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...
StocksToTrade | Sponsored
RSVP: Charles Payne’s Cash Flow Workshop
Did you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? ...
Unstoppable Prosperity | Sponsored
Nvidia needs this one obscure firm
In my new investigation, I detail why this is the single most important factor in the future of AI. I expla...
Porter & Company | Sponsored